Apyx Medical Corporation - Common Stock (APYX)

Apyx Medical (NASDAQ:APYX) reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces. Total revenue for the quarter ended June

Babcock & Wilcox delivers energy and emissions control solutions to industrial and utility clients worldwide.

This cybersecurity firm delivers risk assessment and vulnerability management solutions to enterprise and government clients worldwide.

Oceaneering International delivers subsea robotics, engineered products, and digital solutions to global energy and defense clients.

EZCORP operates a broad network of pawn stores and digital platforms, serving consumers seeking short-term credit and value-priced goods.

Satellogic delivers real-time Earth observation data and analytics, serving commercial and government clients across multiple industries.

Apyx Medical (APYX) Q1 2026 Earnings Transcript

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

As November 20, 2025, unfolds, global financial markets present a landscape of intriguing contrasts, marked by the persistent, transformative power of artificial intelligence and a growing undercurrent of investor caution. While select sectors and geographies celebrate robust growth fueled by technological advancements and strong earnings, broader market sentiment in key

Apyx Medical Q3 2025 earnings beat expectations with a 50% EPS surprise and strong revenue. Stock surges on successful AYON Body Contouring System launch.

APYX Medical Corp reported Q2 2025 results with revenue of $11.37M, missing estimates, but a narrower EPS loss of -$0.09. Stock shows muted reaction amid commercial expansion plans.